title: Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
abstract: OBJECTIVE
  Early detection is an essential prognostic factor in colorectal cancer (CRC) recurrence. Our aim was to evaluate diagnostic performances of (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET)/computed tomography (CT) as compared with CT in the detection of CRC recurrence.
  
  
  METHODS
  Data of patients with suspected CRC recurrence and in whom both FDG-PET/CT and CT were performed were analyzed. All detected lesions were characterized according to their number, size, and localization. Positive histological or radiological follow-up was considered as the 'gold standard'. Diagnostic performances of FDG-PET/CT and CT were calculated by lesion, globally and with respect to the site of recurrence.
  
  
  RESULTS
  One hundred and seventy-six true-positive lesions were identified in 71 patients. CT scan was positive in 58 (82%) patients and FDG-PET/CT in 70 (98%) patients. In per lesion analysis, the global accuracy of FDG-PET/CT in detection of lesions was of 88% (sensitivity = 95%, specificity = 54%), which was higher than that of CT (53%, sensitivity = 55%, specificity = 43%), particularly in case of lymph nodes metastases (100 vs. 35%) and locoregional lesions (100 vs. 39%) (P<0.0001). FDG-PET/CT modified the clinical management in 31 patients.
  
  
  CONCLUSIONS
  FDG-PET/CT is more sensitive than CT for diagnosis of CRC recurrence and can modify the management in 40% of patients.
authors.affiliation: Institut des Maladies de l'Appareil Digestif-CIC INSERM et Service d'Hépato-Gastroentérologie, CHU de Nantes, Nantes Saint-Herblain, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Deleau
authors.forename: Bruno
authors.initials: B
authors.lastname: Buecher
authors.forename: Caroline
authors.initials: C
authors.lastname: Rousseau
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: Mathurin
authors.initials: M
authors.lastname: Flamant
authors.forename: Stanislas Bruley
authors.initials: SB
authors.lastname: des Varannes
authors.forename: Eric
authors.initials: E
authors.lastname: Frampas
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Galmiche
authors.forename: Tamara
authors.initials: T
authors.lastname: Matysiak-Budnik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000000981:diagnostic imaging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000556:secondary; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18